Transformation reversion induced in jb6 rt101 cells by ap-1 inhibitors

Zigang Dong, Vadim Lavrovsky, Nancy H. Colburn

Research output: Contribution to journalArticlepeer-review

79 Scopus citations

Abstract

The present study was directed to characterizing the reversion of neoplastic epidermal JB6 RT101 cells by AP-1 inhibiting drugs. Treatment of tumorigenic JB6 RT101 cells with retinoic acid (RA), fluocinolone acetonide (FA) or forskolin (FN) induced drug dependent (reversible) reversion of transformation. A synergistic effect on reversion was found with the three drugs in combination. Cells reverted by these three drugs also showed reduced levels of AP-1 transcription factor activity. After long term exposure of RT101 cells to FA, enrichment of flat revertants occurred in the population while a few unreverted cells formed foci. These unreverted cells appeared to be FA-resistant. Cloning of cells following RA treatment revealed stable reversion at least 2 months after drug withdrawal. Stable revertants showed lower basal AP-1 activity than RT101 cells (P < 0.01) and unstable revertants returned to transformed phenotype and elevated AP-1 activity within days following drug withdrawal. To our knowledge this is the first demonstration that drug induced reversion co-selects for reduced AP-1 activity. These data suggest that the JB6 RT101 cell line is a useful cell model for studying reversion of transformation and that inhibition of AP-1 activity may be one molecular mechanism of reversion. Considering the development of resistance with FA alone and the relative inefficiency of RA or FN alone, combinations of the three AP-1 activity inhibitors RA, FA and FN may be useful for further animal and clinical studies.

Original languageEnglish (US)
Pages (from-to)749-756
Number of pages8
JournalCarcinogenesis
Volume16
Issue number4
DOIs
StatePublished - Apr 1995

Fingerprint Dive into the research topics of 'Transformation reversion induced in jb6 rt101 cells by ap-1 inhibitors'. Together they form a unique fingerprint.

Cite this